Crossover Versus Stabilometric Platform in Parkinson's Disease

Effect of Two Different Rehabilitation Programs on Balance in Parkinsonian Patients: Crossover Versus Stabilometric Platform

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02098577

Acronym

PDvsCOPD

Enrollment

Registered

2014-03-28

Start date

2013-06-30

Completion date

2014-02-28

Last updated

2014-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease

Keywords

Balance

Brief summary

The aims of this study is to assess the efficacy of the crossover on balance in Parkinsonian patients and compare this results with the results of a control group of patients treated with a stabilometric platform.

Detailed description

Parkinson's disease (PD) is a neurodegenerative disorder characterized by different motor symptoms (rigidity, akinesia, tremor and impairment of balance and gait). Even though pharmacological treatment has changed the natural course of the disease, balance worsens over time and leads to falls. The aims of this study is to assess the efficacy of the crossover (group 1) on balance in Parkinsonian patients and compare this results with the results of a control group of patients treated with a stabilometric platform (group 2). The group 1 executed 6 days/week for a 4-weeks cycle a crossover protocol based on the first 4 level of resistance and a training which lasts at most 5 minutes. The group 2 executed 6 days/week for a 4-weeks cycle different exercises with the stabilometric platform in monopodalic and in bipodalic standing.

Interventions

OTHERCrossover

Crossover cycle

OTHERStabilometric Platform

This Stabilometric plate allows to assess the balance with an objective and reliable measurement, in both standard static or dynamic unstable condition

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

50 Years to 75 Years

Healthy volunteers

Inclusion criteria

* PD in stage III Hoen&Yahr according to Gelb et la. with the ability to walk without any assistance and with Mini Mental State Examination (MMSE) score \> 26

Exclusion criteria

* MMSE \< 26 * Coexistence of other neurological diseases * PD patients with relevant orthopedic, rheumatic and muscular conditions

Design outcomes

Primary

Measure	Time frame	Description
BBS	One month	Berg Balance Scale

Secondary

Measure	Time frame	Description
6MWT	One month	Six minutes walking test
TUG	One month	Time up and Go test
UPDRS II	One month	Unified Parkinson's disease Rating Scale II
UPDRS III	One month	Unified Parkinson's disease Rating Scale III

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026